FibroBiologics to Present at the Advanced Wound Care Summit USA
FibroBiologics (Nasdaq: FBLG), a clinical-stage biotechnology company focused on developing fibroblast-based therapeutics, announced its participation in the Advanced Wound Care Summit USA in Boston on July 15, 2025.
CEO Pete O'Heeron will present the company's recent research advances in fibroblast-based technology for wound healing and psoriasis. The presentation will highlight CYWC628 therapy for diabetic foot ulcers, with a Phase 1/2 clinical trial planned to begin later in 2025. The therapy aims to leverage the body's natural regenerative processes rather than just managing symptoms.
FibroBiologics (Nasdaq: FBLG), un'azienda biotecnologica in fase clinica specializzata nello sviluppo di terapie a base di fibroblasti, ha annunciato la sua partecipazione al Advanced Wound Care Summit USA che si terrà a Boston il 15 luglio 2025.
Il CEO Pete O'Heeron presenterà i recenti progressi della società nella tecnologia basata sui fibroblasti per la guarigione delle ferite e la psoriasi. La presentazione metterà in evidenza la terapia CYWC628 per le ulcere del piede diabetico, con uno studio clinico di Fase 1/2 previsto per la fine del 2025. Questa terapia punta a sfruttare i processi rigenerativi naturali del corpo, andando oltre la semplice gestione dei sintomi.
FibroBiologics (Nasdaq: FBLG), una empresa biotecnológica en etapa clínica enfocada en el desarrollo de terapias basadas en fibroblastos, anunció su participación en el Advanced Wound Care Summit USA en Boston el 15 de julio de 2025.
El CEO Pete O'Heeron presentará los avances recientes de la compañía en tecnología basada en fibroblastos para la cicatrización de heridas y la psoriasis. La presentación destacará la terapia CYWC628 para úlceras del pie diabético, con un ensayo clínico de fase 1/2 planificado para comenzar a finales de 2025. La terapia busca aprovechar los procesos regenerativos naturales del cuerpo, en lugar de solo manejar los síntomas.
FibroBiologics (나스닥: FBLG)는 섬유아세포 기반 치료제 개발에 주력하는 임상 단계의 생명공학 회사로, 2025년 7월 15일 보스턴에서 열리는 Advanced Wound Care Summit USA에 참여한다고 발표했습니다.
CEO 피트 오히런은 상처 치유와 건선 치료를 위한 섬유아세포 기반 기술의 최근 연구 성과를 발표할 예정입니다. 발표에서는 당뇨병성 족부 궤양 치료제인 CYWC628 치료법을 중점적으로 다루며, 2025년 말에 1/2상 임상시험을 시작할 계획입니다. 이 치료법은 증상 관리에 그치지 않고 신체의 자연 재생 과정을 활용하는 것을 목표로 합니다.
FibroBiologics (Nasdaq : FBLG), une société de biotechnologie en phase clinique spécialisée dans le développement de thérapies à base de fibroblastes, a annoncé sa participation au Advanced Wound Care Summit USA à Boston le 15 juillet 2025.
Le PDG Pete O'Heeron présentera les avancées récentes de la société dans la technologie basée sur les fibroblastes pour la cicatrisation des plaies et le psoriasis. La présentation mettra en avant la thérapie CYWC628 pour les ulcères du pied diabétique, avec un essai clinique de phase 1/2 prévu pour la fin de l'année 2025. Cette thérapie vise à exploiter les processus naturels de régénération du corps plutôt que de se contenter de gérer les symptômes.
FibroBiologics (Nasdaq: FBLG), ein biotechnologisches Unternehmen in der klinischen Phase, das sich auf die Entwicklung fibroblastbasierter Therapeutika spezialisiert hat, kündigte seine Teilnahme am Advanced Wound Care Summit USA in Boston am 15. Juli 2025 an.
CEO Pete O'Heeron wird die jüngsten Forschungsergebnisse des Unternehmens zur fibroblastbasierten Technologie für Wundheilung und Psoriasis vorstellen. Die Präsentation wird die CYWC628-Therapie für diabetische Fußgeschwüre hervorheben, für die eine Phase-1/2-Studie Ende 2025 geplant ist. Die Therapie zielt darauf ab, die natürlichen regenerativen Prozesse des Körpers zu nutzen, anstatt nur Symptome zu behandeln.
- None.
- None.
HOUSTON, July 11, 2025 (GLOBE NEWSWIRE) -- FibroBiologics, Inc. (Nasdaq: FBLG) (“FibroBiologics”), a clinical-stage biotechnology company with 275+ patents issued and pending with a focus on the development of therapeutics and potential cures for chronic diseases using fibroblasts and fibroblast-derived materials, today announced that Founder and Chief Executive Officer, Pete O’Heeron, will present at the Advanced Wound Care Summit USA in Boston, Massachusetts, on July 15, 2025. The presentation will include recent research advances using fibroblast-based technology for indications such as wound healing and psoriasis.
“The Advanced Wound Care Summit is an ideal forum to showcase how FibroBiologics is pioneering the next generation of wound healing through our fibroblast-based technology," said Mr. O’Heeron. "Our CYWC628 therapy represents a fundamentally different approach to treating diabetic foot ulcers, one that taps into the body's natural regenerative processes rather than simply managing symptoms. With our Phase 1/2 clinical trial set to kick off later this year, we are poised to deliver potentially transformative outcomes for patients with limited treatment options and high recurrence rates.”
Details of the presentation are as follows:
Date: Tuesday, July 15, 2025
Time: 2 p.m. ET
Location: Marriott Courtyard Boston Downtown
The Advanced Wound Care Summit, taking place July 15–17, will bring together global leaders in wound care innovation, clinical research, and advanced therapeutics to address unmet needs in chronic wound management. With a focus on accelerating product development and enhancing patient outcomes, the summit will feature keynote presentations, interactive panels, and strategic networking opportunities.
For more information, please visit FibroBiologics’ website or email FibroBiologics at info@fibrobiologics.com.
Cautionary Statement Regarding Forward-Looking Statements
This communication contains "forward-looking statements" as defined in the Private Securities Litigation Reform Act of 1995. Forward-looking statements include information concerning plans for, and the anticipated timing of the initiation of and results from, FibroBiologics’ current and future preclinical studies, clinical trials and research and development programs, and the potential clinical benefits of fibroblasts and fibroblast-derived materials. These forward-looking statements are based on FibroBiologics' management's current expectations, estimates, projections and beliefs, as well as a number of assumptions concerning future events. These forward-looking statements are not guarantees of future performance, conditions or results, and involve a number of known and unknown risks, uncertainties, assumptions and other important factors, many of which are outside FibroBiologics' management's control, that could cause actual results to differ materially from the results discussed in the forward-looking statements, including those set forth under the caption "Risk Factors" and elsewhere in FibroBiologics' annual, quarterly and current reports (i.e., Form 10-K, Form 10-Q and Form 8-K) as filed or furnished with the SEC and any subsequent public filings. Copies are available on the SEC's website, www.sec.gov. These risks, uncertainties, assumptions and other important factors include, but are not limited to: (a) risks related to FibroBiologics' liquidity and its ability to maintain capital resources sufficient to conduct its business; (b) expectations regarding the initiation, progress and expected results of our R&D efforts and preclinical studies; (c) the unpredictable relationship between R&D and preclinical results and clinical study results; and (d) the ability of FibroBiologics to successfully prosecute its patent applications. Forward-looking statements speak only as of the date they are made. Readers are cautioned not to put undue reliance on forward-looking statements, and FibroBiologics assumes no obligation and, except as required by law, does not intend to update, or revise these forward-looking statements, whether as a result of new information, future events, or otherwise. FibroBiologics gives no assurance that it will achieve its expectations.
About FibroBiologics
Based in Houston, FibroBiologics is a clinical-stage biotechnology company developing a pipeline of treatments and seeking potential cures for chronic diseases using fibroblast cells and fibroblast-derived materials. FibroBiologics holds 275+ US and internationally issued patents/patents pending across various clinical pathways, including wound healing, multiple sclerosis, disc degeneration, psoriasis, orthopedics, human longevity, and cancer. FibroBiologics represents the next generation of medical advancement in cell therapy and tissue regeneration. For more information, visit www.FibroBiologics.com.
General Inquiries:
info@fibrobiologics.com
Investor Relations:
Nic Johnson
Russo Partners
(212) 845-4242
fibrobiologicsIR@russopr.com
Media Contact:
Liz Phillips
Russo Partners
(347) 956-7697
Elizabeth.phillips@russopartnersllc.com
FAQ
When and where will FibroBiologics (FBLG) present at the Advanced Wound Care Summit 2025?
What will FibroBiologics present about CYWC628 therapy at the Advanced Wound Care Summit?
How many patents does FibroBiologics (FBLG) currently have?
What therapeutic areas is FibroBiologics focusing on?
